FDA Warning Letter Cites Significant CGMP Violations at Tom’s of Maine Factory - Happi | Household And Personal Products Industry
FDA issued a Warning Letter to Tom's of Maine for significant CGMP violations at its factory, indicating potential regulatory action and need for immediate corrective measures.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Tom's of Maine and potentially other manufacturers in the personal care/pharmaceutical industry, especially those with OTC drug products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; typically 15 working days from receipt of the warning letter.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA cited significant Current Good Manufacturing Practice (CGMP) violations at Tom's of Maine factory, which may lead to enforcement actions.
Who it affects
Tom's of Maine and potentially other manufacturers in the personal care/pharmaceutical industry, especially those with OTC drug products.
What you must do
Tom's of Maine must address the violations, implement corrective actions, and respond to the FDA within the specified timeframe (typically 15 working days).
Deadline
Not specified in the excerpt; typically 15 working days from receipt of the warning letter.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Supreme Court Temporarily Blocks Ruling Barring Telehealth And Pharmacy Access To Mifepristone - Health Affairs
- FDA Proposes to Eliminate "Adequate Provision" for Broadcast Prescription Drug Advertising - foleyhoag.com
- Connecticut Law Imposes New Requirements on Pharmaceutical Manufacturers, Defined to Include Device and Cosmetic Manufacturers, that Employ “Pharmaceutical Sales Representatives” - mintz.com
- FDA Issues Warning to Sanofi About API CGMP Deviations, Puts Clinical Hold on Atara Immunotherapies - biopharminternational.com
- Fourth Circuit Holds cGMP Violations Do Not Create False Claims Under Medicare and Medicaid - wilmerhale.com